Endometriosis drugs: Key market research findings
- Rising adoption of OCPs spurs market growth
- The Americas dominates the market geographically
- Key vendors – AbbVie, AstraZeneca, Bayer HealthCare, and Pfizer
Technavio’s market research analysts predict the global endometriosis drugs market to grow at a CAGR of around 2% between 2016 and 2020. The market’s growth is driven by the increasing adoption of oral contraceptive pills (OCPs). OCPs also referred to as hormonal pills and contain female hormones like estrogen and progestin, which are similar to the ones produced by the ovaries. Apart from its application as a contraceptive, these hormone pills are also effective in the treatment of endometriosis. During 2015, the Americas dominated the global endometriosis market by accounting for almost 49% of the overall market share. Rising awareness of endometriosis coupled with the subsequent availability therapeutic options are factors that will boost growth in the endometriosis drugs market in the Americas by 2020.
The new market research report from Technavio presents a breakdown and analysis of the endometriosis drugs segments based on the type of therapy.
“Recently, the market has been witnessing a shift towards the development of intrauterine devices (IUDs). This is triggered by the growing awareness about many unwanted side effects brought on by other forms of therapy. Though IUDs were initially developed for birth control, their use is being extended to treat endometriosis,” says Barath Palada, Lead Analyst, Pharma, Technavio Research.
In 2015, the hormone therapy segment accounted for almost 71% of the market’s revenue to become the key revenue generator in the global endometriosis market. In endometriosis, hormones such as estrogen, progesterone, testosterone, and progestin are used for treatment. Hormone therapy effectively reduces the production of estrogen in the female body, leading to the inhibition of the growth in the tissue.
The key vendors in the global endometriosis drugs market include AbbVie, AstraZeneca, Bayer HealthCare, and Pfizer. The competition in the global endometriosis market is intense due to the presence of several well-established vendors such as AbbVie, Bayer Healthcare, and AstraZeneca. The competitive environment in this market is expected to intensify with an increase in product or service extensions. The competition among the vendors is expected to increase as they enter into partnerships or acquire distributors to increase their sales and expand their businesses worldwide.
A more detailed analysis is available in the Technavio report, Global Endometriosis Drugs Market 2016-2020.
We can customize reports by other regions and specific segments upon request.
Other related reports:
